IL238563A0 - Cancer treatment with pomalidomide in particular with kidney failure - Google Patents

Cancer treatment with pomalidomide in particular with kidney failure

Info

Publication number
IL238563A0
IL238563A0 IL238563A IL23856315A IL238563A0 IL 238563 A0 IL238563 A0 IL 238563A0 IL 238563 A IL238563 A IL 238563A IL 23856315 A IL23856315 A IL 23856315A IL 238563 A0 IL238563 A0 IL 238563A0
Authority
IL
Israel
Prior art keywords
pomalidomide
cancer
treatment
impaired subject
renally impaired
Prior art date
Application number
IL238563A
Other languages
English (en)
Hebrew (he)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of IL238563A0 publication Critical patent/IL238563A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL238563A 2012-11-05 2015-04-30 Cancer treatment with pomalidomide in particular with kidney failure IL238563A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722722P 2012-11-05 2012-11-05
US201361764466P 2013-02-13 2013-02-13
PCT/US2013/068237 WO2014071280A1 (en) 2012-11-05 2013-11-04 Treatment of cancer with pomalidomide in a renally impaired subject

Publications (1)

Publication Number Publication Date
IL238563A0 true IL238563A0 (en) 2015-06-30

Family

ID=50628132

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238563A IL238563A0 (en) 2012-11-05 2015-04-30 Cancer treatment with pomalidomide in particular with kidney failure

Country Status (15)

Country Link
US (1) US20150297579A1 (enExample)
EP (1) EP2914112A4 (enExample)
JP (1) JP2015535291A (enExample)
CN (1) CN104902754A (enExample)
AU (1) AU2013337352A1 (enExample)
BR (1) BR112015010039A2 (enExample)
CA (1) CA2889987A1 (enExample)
EA (1) EA201590883A1 (enExample)
HK (1) HK1214552A1 (enExample)
IL (1) IL238563A0 (enExample)
MX (1) MX2015005548A (enExample)
NI (1) NI201500063A (enExample)
PH (1) PH12015501002A1 (enExample)
SG (1) SG11201503456TA (enExample)
WO (1) WO2014071280A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507759WA (en) * 2013-04-02 2015-10-29 Celgene Corp Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
WO2019051125A1 (en) 2017-09-06 2019-03-14 Translational Drug Development, Llc AMINOBENZIMIDAZOLE DERIVATIVES, TREATMENTS AND METHODS FOR INHIBITING HISTONE DEACETYLASE
EP3297674B1 (en) * 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
CN105456232A (zh) * 2015-09-08 2016-04-06 刘剑 一种泊马度胺速溶膜剂及其制备方法
AU2016394945A1 (en) * 2016-03-02 2018-10-11 Translational Drug Development Llc Aminobenzimidazole derivatives
WO2018013689A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN108721304B (zh) * 2017-04-17 2020-10-16 北京大学 用于治疗肿瘤的药物组合物及其用途
AR119715A1 (es) 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
GB202012160D0 (en) * 2020-08-05 2020-09-16 Vicore Pharma Ab New compositions
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP5339588B2 (ja) * 2008-11-10 2013-11-13 国立大学法人 新潟大学 サリドマイドまたはその誘導体を有効成分とする統合失調症の治療薬
JP5553275B2 (ja) * 2010-03-31 2014-07-16 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
JP2014517915A (ja) * 2011-04-18 2014-07-24 セルジーン コーポレイション 多発性骨髄腫治療のためのバイオマーカー
EP3096142A3 (en) * 2011-04-29 2017-03-08 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Also Published As

Publication number Publication date
PH12015501002A1 (en) 2015-07-27
HK1214552A1 (zh) 2016-07-29
SG11201503456TA (en) 2015-05-28
WO2014071280A1 (en) 2014-05-08
JP2015535291A (ja) 2015-12-10
EA201590883A1 (ru) 2015-09-30
BR112015010039A2 (pt) 2017-07-11
US20150297579A1 (en) 2015-10-22
CA2889987A1 (en) 2014-05-08
EP2914112A4 (en) 2016-06-15
AU2013337352A1 (en) 2015-05-21
CN104902754A (zh) 2015-09-09
NI201500063A (es) 2015-09-10
MX2015005548A (es) 2016-01-15
EP2914112A1 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL267242B (en) Cancer treatment
IL238563A0 (en) Cancer treatment with pomalidomide in particular with kidney failure
EP2903644A4 (en) TREATMENT OF CANCER
GB201217892D0 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
IL232713A0 (en) erbb3 mutations in cancer
GB2497886B (en) Hair treatment methods
EP2864362A4 (en) ANTICANCER TREATMENT
DK2872176T3 (en) Cancer treatment
ZA201501562B (en) Treatment regimens
GB201204981D0 (en) Pre-harvest treatment
GB201222563D0 (en) Cancer treatment
GB201217890D0 (en) Treatment of cancer
GB2500999B (en) Hair treatment methods
GB2498582B (en) Improvements in medical identity bracelets
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201208296D0 (en) Treatment of cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201206294D0 (en) Improved toenail treatment
GB201211135D0 (en) Treatment
GB201208690D0 (en) Treatment
GB201212604D0 (en) New treatment
GB201214551D0 (en) Anticancer treatment